Approach

Summary

Licensing status

Publication and contact information

Drug platforms

A multifunctional, aptamer-based DNA nanoassembly (AptNA) for targeted cancer therapy

In vitro and cell culture studies suggest AptNAs that deliver small molecule and antisense compounds could help treat cancer. In vitro engineering and photo cross-linking led to the production of self-assembling, acrydite-modified DNA aptamer nanoassemblies which could carry antisense oligonucleotides or cancer drugs. In cultured, drug-resistant leukemia cells, an AptNA able to bind to leukemia cells and carrying doxorubicin and an antisense oligonucleotide targeting P glycoprotein (MDR1; ABCB1; P-gp; CD243) increased cytotoxicity compared with an AptNA carrying a random antisense oligonucleotide. Next steps include testing the AptNA system in vivo in a mouse model of leukemia.

SciBX 7(2); doi:10.1038/scibx.2014.68
Published online Jan. 16, 2014

Unpatented; licensing status not applicable

Wu, C. et al. J. Am. Chem. Soc.; published online Nov. 18, 2013;
doi:10.1021/ja4094617
Contact: Weihong Tan, University of Florida, Gainesville, Florida
e-mail:
tan@chem.ufl.edu